Fmr Has Upped By $5.09 Million Its Tech Data (TECD) Stake; Celldex Therapeutics (CLDX) SI Decreased By 1.71%

January 14, 2018 - By Kurt Siggers

Fmr Llc increased Tech Data Corp (TECD) stake by 1.46% reported in 2017Q3 SEC filing. Fmr Llc acquired 57,865 shares as Tech Data Corp (TECD)’s stock rose 6.40%. The Fmr Llc holds 4.03M shares with $357.83 million value, up from 3.97M last quarter. Tech Data Corp now has $4.00 billion valuation. The stock increased 0.20% or $0.21 during the last trading session, reaching $104.85. About 263,862 shares traded. Tech Data Corporation (NASDAQ:TECD) has risen 41.82% since January 14, 2017 and is uptrending. It has outperformed by 25.12% the S&P500.

Celldex Therapeutics Incorporated (NASDAQ:CLDX) had a decrease of 1.71% in short interest. CLDX’s SI was 7.75 million shares in January as released by FINRA. Its down 1.71% from 7.89 million shares previously. With 876,000 avg volume, 9 days are for Celldex Therapeutics Incorporated (NASDAQ:CLDX)’s short sellers to cover CLDX’s short positions. The SI to Celldex Therapeutics Incorporated’s float is 6.69%. The stock decreased 2.10% or $0.06 during the last trading session, reaching $2.8. About 1.13M shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 20.62% since January 14, 2017 and is downtrending. It has underperformed by 37.32% the S&P500.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has market cap of $380.76 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It currently has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

Among 13 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Celldex Therapeutics had 24 analyst reports since August 11, 2015 according to SRatingsIntel. As per Tuesday, March 8, the company rating was maintained by Cowen & Co. The rating was downgraded by Leerink Swann to “Market Perform” on Monday, March 7. TH Capital maintained the stock with “Buy” rating in Tuesday, August 11 report. The company was maintained on Tuesday, August 11 by Oppenheimer. Jefferies downgraded it to “Hold” rating and $4 target in Tuesday, March 8 report. On Monday, March 7 the stock rating was downgraded by Wedbush to “Neutral”. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Buy” rating given on Tuesday, March 8 by H.C. Wainwright. Cowen & Co maintained the stock with “Buy” rating in Tuesday, June 6 report. The stock has “Hold” rating by Jefferies on Tuesday, August 9. The stock has “Buy” rating by H.C. Wainwright on Tuesday, November 7.

Fmr Llc decreased Rice Energy Inc (NYSE:RICE) stake by 152,270 shares to 2.71 million valued at $78.56 million in 2017Q3. It also reduced First Comwlth Finl Corp Pa (NYSE:FCF) stake by 108,700 shares and now owns 1.39M shares. Terreno Rlty Corp (NYSE:TRNO) was reduced too.

Among 8 analysts covering Tech Data Corp (NASDAQ:TECD), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Tech Data Corp had 19 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was maintained by Citigroup on Thursday, September 22 with “Sell”. The firm has “Buy” rating given on Tuesday, September 20 by Bank of America. The firm earned “Mkt Perform” rating on Wednesday, November 25 by Raymond James. The company was maintained on Friday, May 27 by Citigroup. The stock of Tech Data Corporation (NASDAQ:TECD) earned “Underperform” rating by Bank of America on Tuesday, August 18. The rating was upgraded by Citigroup on Friday, June 2 to “Neutral”. On Friday, September 1 the stock rating was maintained by Loop Capital Markets with “Buy”. The rating was maintained by Raymond James with “Hold” on Tuesday, November 28. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, September 20. On Thursday, August 24 the stock rating was initiated by Loop Capital Markets with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Kurt Siggers







Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: